
Opinion|Videos|May 29, 2025
Expert Insights in the Management of Early-Stage NSCLC With Limited Nodal or Oligometastatic Disease
Panelists discuss how advanced radiotherapy techniques, including stereotactic body radiation therapy (SBRT), combined with immunotherapy, have emerged as preferred treatment approaches for unresectable early-stage non–small cell lung cancer (NSCLC).
Advertisement
Video content above is prompted by the following:
Biomarker Testing for NSCLC
Medical professionals routinely perform the following biomarker tests:
Driver Mutations:
- EGFR mutations (exon 19 deletions, L858R, T790M, etc)
- ALK rearrangements
- ROS1 fusions
- BRAF V600E mutations
- NTRK fusions
- MET exon 14 skipping mutations
- RET fusions
- KRAS G12C mutations
Immunotherapy Biomarkers:
- PD-L1 expression (tumor proportion score)
- Tumor mutational burden
- Microsatellite instability status
Testing Methodology:
- Next-generation sequencing panels
- Immunohistochemistry for PD-L1 expression
- Fluorescence in situ hybridization for gene rearrangements
Timing:
- Recommended at diagnosis of advanced disease
- Increasingly recommended for early-stage disease to guide adjuvant therapy decisions
- Consider repeat testing at progression to identify resistance mechanisms
Biomarker results help determine eligibility for targeted therapies and immunotherapy, which may be considered in the adjuvant setting or upon disease progression after initial treatment.
Advertisement
Related to this article

The EC approved every-6-week maintenance dosing and shorter 350-mg infusions for cemiplimab across all 6 EU indications.

Faculty convened at an OncLive Scientific Interchange and Workshop to guide oncology fellows through designing a cancer clinical trial development program, from concept to approval.

Narek Shaverdian, MD, outlines how novel strategies may reshape unresectable stage III NSCLC management.

The FDA granted fast track designation to elticertinib for pretreated EGFR exon 20 insertion–mutated NSCLC.

Deepa Rangachari, MD, discusses community oncology training, goal-concordant mentorship, genomic fluency, and multidisciplinary care.

Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
3
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
4
Testing, Timing, and Toxicity: Maximizing Tepotinib’s Durable Benefit in MET Exon 14 Skipping NSCLC
5


